Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
6 studies found for:    RENAL CANCER E7080
Hide Display Options

Display Options

Study Details
Participant Details
Rank Status Study
1 Active, not recruiting A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment
Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: Lenvatinib;   Drug: Everolimus
2 Not yet recruiting Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
Interventions: Drug: lenvatinib;   Drug: everolimus;   Drug: pembrolizumab;   Drug: Sunitinib
3 Active, not recruiting Study of Lenvatinib in Combination With Everolimus in Patients With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)
Condition: Carcinoma, Renal Cell
Interventions: Drug: Lenvatinib;   Drug: Everolimus
4 Recruiting Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors
Condition: Tumors
Interventions: Drug: Lenvatinib;   Drug: Pembrolizumab
5 Completed A Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies.
Conditions: Advanced Solid Tumors;   Lymphomas
Intervention: Drug: Lenvatinib
6 Active, not recruiting
Has Results
An Open Label Phase I Dose Escalation Study Of E7080
Condition: Solid Tumor or Lymphoma
Intervention: Drug: Lenvatinib

Indicates status has not been verified in more than two years